{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:42:45Z","timestamp":1793781765195,"version":"4.6.1"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011404","name":"Indivior PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011404","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000764","name":"King's College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000764","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009362","name":"South London and Maudsley NHS Foundation Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009362","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009360","name":"King's College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009360","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.eclinm.2023.102311","type":"journal-article","created":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T07:20:12Z","timestamp":1700205612000},"page":"102311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care\u00a0medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1307-2498","authenticated-orcid":false,"given":"John","family":"Marsden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Kelleher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eilish","family":"Gilvarry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Mitcheson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jatinder","family":"Bisla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Cape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Cowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Dewhurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5227-567X","authenticated-orcid":false,"given":"Will","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Hearn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9137-5005","authenticated-orcid":false,"given":"Natalie","family":"Lowry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"McCusker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey","family":"Myton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Quarshie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Vanderwaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April","family":"Wareham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dyfrig","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zo\u00eb","family":"Hoare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2023.102311_bib2","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/j.1360-0443.2006.01495.x","article-title":"Systematic disease among cases of fatal opioid toxicity","volume":"101","author":"Darke","year":"2006","journal-title":"Addiction"},{"key":"10.1016\/j.eclinm.2023.102311_bib4","author":"Australian National Drug and Alcohol Research Centre"},{"key":"10.1016\/j.eclinm.2023.102311_bib5","author":"Office for National Statistics"},{"key":"10.1016\/j.eclinm.2023.102311_bib7","author":"Centers for Disease Control and Prevention National Center for Health Statistics"},{"key":"10.1016\/j.eclinm.2023.102311_bib8","series-title":"Diagnostic and statistical manual of mental disorders","year":"2013"},{"key":"10.1016\/j.eclinm.2023.102311_bib10","author":"Department of Health and Social Care"},{"key":"10.1016\/j.eclinm.2023.102311_bib12","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.drugalcdep.2008.07.017","article-title":"Benzodiazepine use among opiate-dependent subjects in buprenorphine maintenance treatment: correlates of use, abuse and dependence","volume":"99","author":"Lavie","year":"2009","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.eclinm.2023.102311_bib13","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","volume":"2009","author":"Mattick","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eclinm.2023.102311_bib14","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"6","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eclinm.2023.102311_bib15","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1111\/add.12971","article-title":"Fatal opioid poisoning: a counterfactual model to estimate the preventive effect of treatment for opioid use disorder in England","volume":"110","author":"White","year":"2015","journal-title":"Addiction"},{"key":"10.1016\/j.eclinm.2023.102311_bib16","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/02791072.2015.1014948","article-title":"Changes in quality of life following buprenorphine treatment: relationship with treatment retention and illicit opioid use","volume":"47","author":"Mitchell","year":"2015","journal-title":"J Psychoact Drugs"},{"key":"10.1016\/j.eclinm.2023.102311_bib17","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/S0140-6736(09)61420-3","article-title":"Effectiveness of community treatments for heroin and crack cocaine addiction in England: a prospective, in-treatment cohort study","volume":"374","author":"Marsden","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2023.102311_bib18","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.drugalcdep.2017.03.013","article-title":"Effectiveness of treatment for opioid use disorder: a national, five-year, prospective, observational study in England","volume":"176","author":"Eastwood","year":"2017","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.eclinm.2023.102311_bib19","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jsat.2014.12.011","article-title":"Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes","volume":"52","author":"Bentzley","year":"2015","journal-title":"J\u00a0Subst Abuse Treat"},{"key":"10.1016\/j.eclinm.2023.102311_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-069857","article-title":"Patients\u2019 perceptions of self-administered dosing to opioid agonist treatment and other changes during the COVID-19 pandemic: a qualitative study","volume":"13","author":"Scott","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.eclinm.2023.102311_bib21","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.drugalcdep.2018.03.052","article-title":"Continuous opioid substitution treatment over five years: heroin use trajectories and outcomes","volume":"188","author":"Eastwood","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.eclinm.2023.102311_bib22","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","article-title":"Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial","volume":"178","author":"Lofwall","year":"2018","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.eclinm.2023.102311_bib23","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0140-6736(18)32259-1","article-title":"Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multi-clinic, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"1073","author":"Haight","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2023.102311_bib24","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1186\/s13063-022-06595-0","article-title":"Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone","volume":"23","author":"Marsden","year":"2022","journal-title":"Trials"},{"key":"10.1016\/j.eclinm.2023.102311_bib25","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1136\/bmj.a2390","article-title":"Improving the reporting of pragmatic trials: an extension of the CONSORT statement","volume":"337","author":"Zwarenstein","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2023.102311_bib26","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","article-title":"Consolidated health economic evaluation reporting standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II good practices task force","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.eclinm.2023.102311_bib27","series-title":"Structured clinical interview for DSM-5 disorders \u2013 research version (SCID-5-RV)","author":"First","year":"2015"},{"key":"10.1016\/j.eclinm.2023.102311_bib28","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1111\/j.1360-0443.2012.03971.x","article-title":"Risk adjustment of heroin treatment outcomes for comparative performance assessment in England","volume":"107","author":"Marsden","year":"2012","journal-title":"Addiction"},{"key":"10.1016\/j.eclinm.2023.102311_bib29","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1192\/bjp.bp.112.111583","article-title":"Cost-effectiveness of injectable opioid treatment vs. oral ,methadone for chronic heroin addiction","volume":"203","author":"Byford","year":"2013","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.eclinm.2023.102311_bib30","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1111\/j.1360-0443.2008.02284.x","article-title":"Development of the treatment outcomes profile","volume":"103","author":"Marsden","year":"2008","journal-title":"Addiction"},{"key":"10.1016\/j.eclinm.2023.102311_bib31","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/add.12472","article-title":"The craving experience questionnaire: a brief, theory-based measure of consummatory desire and craving","volume":"109","author":"May","year":"2014","journal-title":"Addiction"},{"key":"10.1016\/j.eclinm.2023.102311_bib32","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10862-015-9529-3","article-title":"The Difficulties in emotion regulation scale short form (DERS-SF): validation and replication in adolescent and adult samples","volume":"38","author":"Kaufman","year":"2016","journal-title":"J Psychopathol Behav Assess"},{"key":"10.1016\/j.eclinm.2023.102311_bib33","series-title":"Methods for mapping between the EQ-5D-5L and the 3L for technology appraisal","author":"Hernandez Alava","year":"2017"},{"key":"10.1016\/j.eclinm.2023.102311_bib34","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal Cognitive Assessment (MoCA): a brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine","year":"2005","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.eclinm.2023.102311_bib35","series-title":"Timeline Follow-back: a Calendar Method for assessing alcohol and drug use. User's guide","author":"Sobell","year":"1996"},{"key":"10.1016\/j.eclinm.2023.102311_bib36","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0376-8716(96)01218-5","article-title":"Stability of opioid craving over time as measured by visual analog scales","volume":"40","author":"McMillan","year":"1996","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.eclinm.2023.102311_bib37","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0006-3223(02)01866-8","article-title":"The 16-item Quick inventory of depressive Symptomatology (QIDS) clinician rating (QIDS-C) and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression","volume":"54","author":"Rush","year":"2003","journal-title":"Biol Psychiatr"},{"key":"10.1016\/j.eclinm.2023.102311_bib38","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1192\/bjp.180.5.461","article-title":"The Work and Social Adjustment Scale: a simple measure of impairment in functioning","volume":"180","author":"Mundt","year":"2002","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.eclinm.2023.102311_bib39","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.drugalcdep.2014.03.018","article-title":"Development of the addiction dimensions for assessment and personalised treatment (ADAPT)","volume":"139","author":"Marsden","year":"2014","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.eclinm.2023.102311_bib40","series-title":"ECDU assessment manual for psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1016\/j.eclinm.2023.102311_bib41","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.drugalcdep.2016.06.006","article-title":"Development and validation of \u2018SURE\u2019: a patient reported outcome measure (PROM) for recovery from drug and alcohol dependence","volume":"165","author":"Neale","year":"2016","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.eclinm.2023.102311_bib42","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S2215-0366(19)30097-5","article-title":"Efficacy and cost-effectiveness of an adjunctive personalised psychosocial intervention in treatment-resistant maintenance opioid agonist therapy: a pragmatic, open-label, randomised controlled trial","volume":"6","author":"Marsden","year":"2019","journal-title":"Lancet Psychiatr"},{"key":"10.1016\/j.eclinm.2023.102311_bib43","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s41669-018-0068-1","article-title":"Which costs matter? Costs included in economic evaluation and their impact on decision uncertainty for stable coronary artery disease","volume":"2","author":"Lomas","year":"2018","journal-title":"Pharmacoecon Open"},{"key":"10.1016\/j.eclinm.2023.102311_bib44","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/sim.7956","article-title":"Combining multiple imputation and bootstrap in the analysis of cost-effectiveness trial data","volume":"38","author":"Brand","year":"2018","journal-title":"Stat Med"},{"key":"10.1016\/j.eclinm.2023.102311_bib45","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/hec.3564","article-title":"Valuing health-related quality of life: an EQ-5D-5L value set for England","volume":"27","author":"Devlin","year":"2017","journal-title":"Health Econ"},{"key":"10.1016\/j.eclinm.2023.102311_bib46","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40273-022-01218-7","article-title":"Estimating the relationship between EQ-5D-5L and EQ-5D-3L: results from a UK population study","volume":"41","author":"Hern\u00e1ndez Alava","year":"2023","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.eclinm.2023.102311_bib47","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s11136-014-0837-y","article-title":"Multiple imputation to deal with missing EQ-5D-3L data: should we impute individual domains or the actual index?","volume":"24","author":"Simons","year":"2015","journal-title":"Qual Life Res"},{"key":"10.1016\/j.eclinm.2023.102311_bib48","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","article-title":"EuroQol: the current state of play","volume":"37","author":"Brooks","year":"1996","journal-title":"Health Policy"},{"key":"10.1016\/j.eclinm.2023.102311_bib50","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s40258-022-00730-3","article-title":"Supply-side cost-effectiveness thresholds: questions for evidence-based policy","volume":"20","author":"Sampson","year":"2022","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.eclinm.2023.102311_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2014.07.035","article-title":"Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy","volume":"144","author":"Greenwald","year":"2014","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.eclinm.2023.102311_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1052113","article-title":"Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder","volume":"13","author":"Laffont","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.eclinm.2023.102311_bib55","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s40262-020-00957-0","article-title":"Population pharmacokinetics of a monthly buprenorphine depot injection for the treatment of opioid use disorder: a combined analysis of phase II and phase III trials","volume":"60","author":"Jones","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.eclinm.2023.102311_bib56","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ebiom.2018.01.039","article-title":"Memory-focused cognitive therapy for cocaine use disorder: theory, procedures and preliminary evidence from an external pilot randomised controlled trial","volume":"29","author":"Marsden","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.eclinm.2023.102311_bib57","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1111\/add.14546","article-title":"Measurement-based care using DSM-5 for opioid use disorder: can we make opioid medication treatment more effective?","volume":"114","author":"Marsden","year":"2019","journal-title":"Addiction"},{"issue":"8","key":"10.1016\/j.eclinm.2023.102311_bib58","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1007\/s00213-020-05563-3","article-title":"Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis","volume":"237","author":"Tardelli","year":"2020","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.eclinm.2023.102311_bib59","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41398-022-02161-z","article-title":"Oxytocin and orexin systems bidirectionally regulate the ability of opioid cues to bias reward seeking","volume":"12","author":"Giannotti","year":"2022","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.eclinm.2023.102311_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103492","article-title":"Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence","volume":"100","author":"Farrell","year":"2022","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.eclinm.2023.102311_bib61","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1097\/ADM.0000000000000647","article-title":"Recovery from opioid use disorder (OUD) after monthly long-acting buprenorphine treatment: 12-month longitudinal outcomes from RECOVER, an observational study","volume":"14","author":"Ling","year":"2020","journal-title":"J Addict Med"},{"key":"10.1016\/j.eclinm.2023.102311_bib62","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1111\/add.15875","article-title":"The opioid use disorder core outcomes set (OUD\u2013COS) for treatment research: findings from a Delphi consensus study","volume":"17","author":"Karnik","year":"2022","journal-title":"Addiction"},{"key":"10.1016\/j.eclinm.2023.102311_bib63","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.156973","article-title":"Modeling buprenorphine reduction of fentanyl-induced respiratory depression","volume":"7","author":"Olofsen","year":"2022","journal-title":"JCI Insight"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023004881?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023004881?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:25:03Z","timestamp":1762899903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537023004881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":55,"alternative-id":["S2589537023004881"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102311","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care\u00a0medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102311","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102311"}}